# Bepreve vs. Alrex in Subjects With Moderate to Severe Allergic Conjunctivitis

> **NCT01443442** · PHASE4 · COMPLETED · sponsor: **Southern California College of Optometry at Marshall B. Ketchum University** · enrollment: 23 (actual)

## Conditions studied

- Allergic Conjunctivitis

## Interventions

- **DRUG:** bepotastine besilate, 1.5%
- **DRUG:** Loteprednol etabonate

## Key facts

- **NCT ID:** NCT01443442
- **Lead sponsor:** Southern California College of Optometry at Marshall B. Ketchum University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-10
- **Primary completion:** 2012-09
- **Final completion:** 2012-12
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2019-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01443442

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01443442, "Bepreve vs. Alrex in Subjects With Moderate to Severe Allergic Conjunctivitis". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01443442. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*